Pharma Market Access Pricing and Reimbursement Conference
October 23-24, 2013 San Francisco, California
The conference will provide attendees with an opportunity to learn about the key developments impacting the future of pharmaceutical pricing and reimbursement, including:
The increasing importance of generating, collecting and analyzing reimbursement evidence early in product development and identifying points of differentiation of a product versus existing standards of care
The impact of Health Technology Assessments (HTAs) on both private and public payer reimbursement decisions
Coverage with Evidence Development (CED) and performance-based risk-sharing agreements, based on long-term outcomes
The role of comparative effectiveness in future clinical trials and reimbursement decisions
Value-base pricing, which requires companies to back up reimbursement claims with strong evidence that products are a good use of money available
Alternative and shared risk pricing schemes
